BACKGROUND: Rate of lung function decline (RLFD) (as FEV(1) percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part due to uncertainty of sample size requirements. METHODS: Sample size requirements for 1:1 randomizations to detect RLFD treatment effects from 20% to 80% were assessed in Epidemiologic Study of CF (ESCF) patients. Effects of measuring FEV(1) 1-4 times per year in studies of 1- to 4-year durations were assessed in 399 patients age ≥ 6 years with FEV(1) ≥ 70%. Impacts of inclusion/exclusion based on risk factors in 2369 ESCF patients were assessed over 1.5 years using semi-annual FEV(1) measures. RESULTS: Increasing study duration and exclusion of lower risk patients (e.g., no P. aeruginosa infection) both substantially reduced requirements. CONCLUSIONS: CF RLFD studies of 1.5 years in duration appear feasible provided that investigators account for the beneficial effects of subject inclusion/exclusion based on risk factors in power estimates.
BACKGROUND: Rate of lung function decline (RLFD) (as FEV(1) percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part due to uncertainty of sample size requirements. METHODS: Sample size requirements for 1:1 randomizations to detect RLFD treatment effects from 20% to 80% were assessed in Epidemiologic Study of CF (ESCF) patients. Effects of measuring FEV(1) 1-4 times per year in studies of 1- to 4-year durations were assessed in 399 patients age ≥ 6 years with FEV(1) ≥ 70%. Impacts of inclusion/exclusion based on risk factors in 2369 ESCF patients were assessed over 1.5 years using semi-annual FEV(1) measures. RESULTS: Increasing study duration and exclusion of lower risk patients (e.g., no P. aeruginosa infection) both substantially reduced requirements. CONCLUSIONS: CF RLFD studies of 1.5 years in duration appear feasible provided that investigators account for the beneficial effects of subject inclusion/exclusion based on risk factors in power estimates.
Authors: W J Morgan; S M Butler; C A Johnson; A A Colin; S C FitzSimmons; D E Geller; M W Konstan; M J Light; H R Rabin; W E Regelmann; D V Schidlow; D C Stokes; M E Wohl; H Kaplowitz; M M Wyatt; S Stryker Journal: Pediatr Pulmonol Date: 1999-10
Authors: Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith Journal: N Engl J Med Date: 1999-01-07 Impact factor: 91.245
Authors: H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl Journal: N Engl J Med Date: 1994-09-08 Impact factor: 91.245
Authors: N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart Journal: J Cyst Fibros Date: 2020-06-07 Impact factor: 5.482
Authors: Michelle N Eakin; Andrew Bilderback; Michael P Boyle; Peter J Mogayzel; Kristin A Riekert Journal: J Cyst Fibros Date: 2011-03-31 Impact factor: 5.482
Authors: J Stuart Elborn; Michael W Konstan; Jennifer L Taylor-Cousar; Isabelle Fajac; Alexander Horsley; Sivagurunathan Sutharsan; Shawn D Aaron; Cori L Daines; Ahmet Uluer; Damian G Downey; Vincenzina V Lucidi; Sanjeev Ahuja; Eric Springman; John Mershon; Ralph Grosswald; Steven M Rowe Journal: J Cyst Fibros Date: 2021-09-17 Impact factor: 5.482
Authors: Michael W Konstan; Jeffrey S Wagener; Donald R Vandevanter; David J Pasta; Ashley Yegin; Lawrence Rasouliyan; Wayne J Morgan Journal: J Cyst Fibros Date: 2012-05-05 Impact factor: 5.482
Authors: Jun Yang; Jason P Eiserich; Carroll E Cross; Brian M Morrissey; Bruce D Hammock Journal: Free Radic Biol Med Date: 2012-05-08 Impact factor: 7.376